Literature DB >> 29296973

High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis.

Katharine A Lombardo1,2, David G Coffey1,3, Alicia J Morales1, Christopher S Carlson4, Andrea M H Towlerton1, Sarah E Gerdts5, Francis K Nkrumah6, Janet Neequaye7, Robert J Biggar8, Jackson Orem9, Corey Casper1,3,4,5,10,11, Sam M Mbulaiteye12, Kishor G Bhatia12, Edus H Warren1,3.   

Abstract

Burkitt lymphoma (BL), the most common pediatric cancer in sub-Saharan Africa, is a malignancy of antigen-experienced B lymphocytes. High-throughput sequencing (HTS) of the immunoglobulin heavy (IGH) and light chain (IGK/IGL) loci was performed on genomic DNA from 51 primary BL tumors: 19 from Uganda and 32 from Ghana. Reverse transcription polymerase chain reaction analysis and tumor RNA sequencing (RNAseq) was performed on the Ugandan tumors to confirm and extend the findings from the HTS of tumor DNA. Clonal IGH and IGK/IGL rearrangements were identified in 41 and 46 tumors, respectively. Evidence for rearrangement of the second IGH allele was observed in only 6 of 41 tumor samples with a clonal IGH rearrangement, suggesting that the normal process of biallelic IGHD to IGHJ diversity-joining (DJ) rearrangement is often disrupted in BL progenitor cells. Most tumors, including those with a sole dominant, nonexpressed DJ rearrangement, contained many IGH and IGK/IGL sequences that differed from the dominant rearrangement by < 10 nucleotides, suggesting that the target of ongoing mutagenesis of these loci in BL tumor cells is not limited to expressed alleles. IGHV usage in both BL tumor cohorts revealed enrichment for IGHV genes that are infrequently used in memory B cells from healthy subjects. Analysis of publicly available DNA sequencing and RNAseq data revealed that these same IGHV genes were overrepresented in dominant tumor-associated IGH rearrangements in several independent BL tumor cohorts. These data suggest that BL derives from an abnormal B-cell progenitor and that aberrant mutational processes are active on the immunoglobulin loci in BL cells.

Entities:  

Year:  2017        PMID: 29296973      PMCID: PMC5728594          DOI: 10.1182/bloodadvances.2016000794

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  54 in total

1.  Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936.

Authors:  J H J M van Krieken; A W Langerak; E A Macintyre; M Kneba; E Hodges; R Garcia Sanz; G J Morgan; A Parreira; T J Molina; J Cabeçadas; P Gaulard; B Jasani; J F Garcia; M Ott; M L Hannsmann; F Berger; M Hummel; F Davi; M Brüggemann; F L Lavender; E Schuuring; P A S Evans; H White; G Salles; P J T A Groenen; P Gameiro; Ch Pott; J J M van Dongen
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

2.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

3.  Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis.

Authors:  Maria Joao Baptista; Eva Calpe; Eva Fernandez; Lluis Colomo; Teresa Marta Cardesa-Salzmann; Pau Abrisqueta; Francesc Bosch; Marta Crespo
Journal:  Leuk Res       Date:  2014-01-13       Impact factor: 3.156

4.  Burkitt's lymphoma and malaria.

Authors:  G W Kafuko; D P Burkitt
Journal:  Int J Cancer       Date:  1970-07-15       Impact factor: 7.396

5.  Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes.

Authors:  U Klein; G Klein; B Ehlin-Henriksson; K Rajewsky; R Küppers
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

6.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

7.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

9.  Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors.

Authors:  Keisuke Horikawa; Stephen W Martin; Sarah L Pogue; Karlee Silver; Kaiman Peng; Kiyoshi Takatsu; Christopher C Goodnow
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

10.  A Public Database of Memory and Naive B-Cell Receptor Sequences.

Authors:  William S DeWitt; Paul Lindau; Thomas M Snyder; Anna M Sherwood; Marissa Vignali; Christopher S Carlson; Philip D Greenberg; Natalie Duerkopp; Ryan O Emerson; Harlan S Robins
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more
  8 in total

1.  Capacity building for hematologic malignancies in Uganda: a comprehensive research, training, and care program through the Uganda Cancer Institute-Fred Hutchinson Cancer Research Center collaboration.

Authors:  Clement D Okello; Henry Ddungu; Abrahams Omoding; Andrea M H Towlerton; Heather Pitorak; Katie Maggard; Sarah Ewart; Warren T Phipps; Thomas S Uldrick; Edus H Warren; Jackson Orem
Journal:  Blood Adv       Date:  2018-11-30

2.  New Clues to Prognostic Biomarkers of Four Hematological Malignancies.

Authors:  Samson Pandam Salifu; Albert Doughan
Journal:  J Cancer       Date:  2022-05-09       Impact factor: 4.478

Review 3.  How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.

Authors:  Satish Gopal; Thomas G Gross
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

4.  Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.

Authors:  Bruno M Grande; Daniela S Gerhard; Aixiang Jiang; Nicholas B Griner; Jeremy S Abramson; Thomas B Alexander; Hilary Allen; Leona W Ayers; Jeffrey M Bethony; Kishor Bhatia; Jay Bowen; Corey Casper; John Kim Choi; Luka Culibrk; Tanja M Davidsen; Maureen A Dyer; Julie M Gastier-Foster; Patee Gesuwan; Timothy C Greiner; Thomas G Gross; Benjamin Hanf; Nancy Lee Harris; Yiwen He; John D Irvin; Elaine S Jaffe; Steven J M Jones; Patrick Kerchan; Nicole Knoetze; Fabio E Leal; Tara M Lichtenberg; Yussanne Ma; Jean Paul Martin; Marie-Reine Martin; Sam M Mbulaiteye; Charles G Mullighan; Andrew J Mungall; Constance Namirembe; Karen Novik; Ariela Noy; Martin D Ogwang; Abraham Omoding; Jackson Orem; Steven J Reynolds; Christopher K Rushton; John T Sandlund; Roland Schmitz; Cynthia Taylor; Wyndham H Wilson; George W Wright; Eric Y Zhao; Marco A Marra; Ryan D Morin; Louis M Staudt
Journal:  Blood       Date:  2019-01-07       Impact factor: 25.476

5.  Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.

Authors:  Samuel Kirimunda; Murielle Verboom; Isaac Otim; Mark Ssennono; Ismail D Legason; Hadijah Nabalende; Martin D Ogwang; Patrick Kerchan; Tobias Kinyera; Ivan Mwebaza; Moses Joloba; Leona W Ayers; Steven J Reynolds; Kishor Bhatia; Olusegun O Onabajo; Michael Hallensleben; Robert J Biggar; Ludmila Prokunina-Olsson; James J Goedert; Rainer Blasczyk; Sam M Mbulaiteye
Journal:  Br J Haematol       Date:  2020-02-18       Impact factor: 8.615

6.  Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.

Authors:  Masato Ikeda; Cooper K Hayes; Samantha J Schaller; Richard Longnecker
Journal:  Blood Adv       Date:  2022-07-26

7.  High purity high yield tandem B and T helper cell isolation for qRT-PCR analysis suitable for basically equipped laboratories.

Authors:  Andrea Maria Summerauer; Lorenzo Colombo; Rodney Ogwang; Christoph Berger; Jan Fehr; Simone Bürgler
Journal:  Malar J       Date:  2018-10-29       Impact factor: 2.979

8.  Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.

Authors:  Xuefeng Niu; Song Li; Pingchao Li; Wenjing Pan; Qian Wang; Ying Feng; Xiaoneng Mo; Qihong Yan; Xianmiao Ye; Jia Luo; Linbing Qu; Daniel Weber; Miranda L Byrne-Steele; Zhe Wang; Fengjia Yu; Fang Li; Richard M Myers; Michael T Lotze; Nanshan Zhong; Jian Han; Ling Chen
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.